Pacira Pharmaceuticals (82P) Stock Price & Analysis
82P Stock Chart & Stats
- Day’s Range
- EUR 32.00 - EUR 32.20
- 52-Week Range
- EUR 15.40 - EUR 34.20
- Previous Close
- EUR 32.20
- Volume
- 0
- Average Volume (3M)
- 0
- Market Cap
- EUR 1.29B
- Enterprise Value
- EUR 1.18B
- Total Cash (Recent Filing)
- EUR 251.03M
- Total Debt (Recent Filing)
- EUR 412.12M
- Price to Earnings (P/E)
- 103.4
- Beta
- 0.62
- Next Earnings
- Mar 04, 2027 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Strong Cash Generation
Strong operating and free cash flow, alongside cash conversion that generally tracks reported earnings, indicates Pacira is generating substantial underlying liquidity. This supports research investment, commercial execution, and balance-sheet resilience while reducing reliance on external financing over the next several quarters.
Expanded Payer Access
Broader reimbursement and formulary access can lower adoption barriers for EXPAREL and ZILRETTA across hospitals and clinical settings. Coverage reaching about 150 million lives provides a durable commercial platform, supporting procedure penetration and product demand beyond individual selling periods.
European Expansion Partnership
The Molteni partnership extends Exparel into additional European markets while assigning regulatory, access, and commercialization work to an established pain-management partner. Pacira retains manufacturing economics and gains potential royalty revenue, creating a structural international growth channel from 2027.
Bears Say
Volatile Profitability
The shift from profit to a sharp loss and back to only modest profitability shows that earnings quality remains inconsistent. Thin operating and net margins leave less protection against execution setbacks, making sustained revenue growth and cost discipline important for financial stability.
Higher Operating Investment
Higher R&D and SG&A spending reflects investment in advancing pipeline programs and commercial operations, but it also raises the revenue threshold needed to expand earnings. If product growth does not outpace these costs, operating leverage and near-term profitability could remain constrained.
NOPAIN Reimbursement Uncertainty
Uncertainty around renewal of CMS NOPAIN reimbursement creates a longer-term access risk for Pacira’s non-opioid pain strategy. Delays or unfavorable rulemaking could affect provider economics and adoption, complicating planning for demand, reimbursement support, and future commercial expansion.
Pacira Pharmaceuticals News
82P FAQ
What was Pacira Pharmaceuticals’s price range in the past 12 months?
What is Pacira Pharmaceuticals’s market cap?
When is Pacira Pharmaceuticals’s upcoming earnings report date?
How were Pacira Pharmaceuticals’s earnings last quarter?
Is Pacira Pharmaceuticals overvalued?
Does Pacira Pharmaceuticals pay dividends?
What is Pacira Pharmaceuticals’s EPS estimate?
How many shares outstanding does Pacira Pharmaceuticals have?
What happened to Pacira Pharmaceuticals’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Pacira Pharmaceuticals?
What is the TipRanks Smart Score and how is it calculated?
Pacira Pharmaceuticals Stock Smart Score
Company Description
Pacira Pharmaceuticals
Operating within the United States, Pacira BioSciences, Inc. is dedicated to providing healthcare professionals and their patients with non-opioid solutions for pain management and regenerative health. Its offerings include EXPAREL, an injectable liposomal bupivacaine suspension, and ZILRETTA, an extended-release injectable suspension of triamcinolone acetonide. Furthermore, the company offers the iovera system, a non-opioid, handheld cryoanalgesia device capable of delivering precisely controlled cold temperatures to targeted nerves. Pacira also develops its unique multivesicular liposome (MVL) drug delivery technology, which encapsulates therapeutic compounds while preserving their inherent molecular structure. Established in 2006, the firm was formerly known as Pacira Pharmaceuticals, Inc. until its name change to Pacira BioSciences, Inc. in April 2019. Its main corporate office is situated in Tampa, Florida.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Frank D. Lee
- Employees
- 827
- Website
- www.pacira.com
- Address
- 2000 Sierra Point Parkway, Brisbane, CA, 94005, US
Pacira Pharmaceuticals (82P) Earnings & Revenues
82P Company Deck
82P Earnings Call
Earnings Call SentimentPositive
The call highlighted solid financial performance (6% revenue growth, robust adjusted EBITDA, strong cash position), meaningful commercial progress (major payer wins covering ~150M lives, EXPAREL and ZILRETTA momentum), important pipeline and manufacturing milestones (PCRX-201 manufacturing, multiple imminent readouts), and a strategic portfolio move (iovera divestiture with up to $140M consideration). Key challenges include softness in elective inpatient soft tissue procedures driven by macroeconomic factors, a decline in gross margin versus prior year, higher R&D and SG&A spend, and modest near-term moderation in EXPAREL volume growth. Overall, the positives — including clear payer wins, pipeline catalysts, cash generation, and strategic partnerships — outweigh the operational and margin headwinds.
View all DE:82P earnings summaries82P Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 16 | 5 | 1 |
| Technical Analysis | 4 | 5 | 1 |
| Moving Averages | 12 | 0 | 0 |